These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 3024818

  • 1. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN, Halsey J, Cox RS, Hirst VK, Blaschke T, Howes AE, Wasserman TH, Urtasun RC, Pajak T, Hancock S.
    Cancer Res; 1987 Jan 01; 47(1):319-22. PubMed ID: 3024818
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of the hypoxic cell radiosensitizer SR-2508: the results of the five to six week drug schedule.
    Coleman CN, Wasserman TH, Urtasun RC, Halsey J, Hirst VK, Hancock S, Phillips TL.
    Int J Radiat Oncol Biol Phys; 1986 Jul 01; 12(7):1105-8. PubMed ID: 3017904
    [Abstract] [Full Text] [Related]

  • 3. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03.
    Coleman CN, Wasserman TH, Urtasun RC, Halsey J, Noll L, Hancock S, Phillips TL.
    Int J Radiat Oncol Biol Phys; 1990 Feb 01; 18(2):389-93. PubMed ID: 2154420
    [Abstract] [Full Text] [Related]

  • 4. Dose-response curves for predicting misonidazole-induced peripheral neuropathy.
    Schwade JG, Makuch RW, Strong JM, Glatstein E.
    Cancer Treat Rep; 1982 Sep 01; 66(9):1743-50. PubMed ID: 6288238
    [Abstract] [Full Text] [Related]

  • 5. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
    Coleman CN, Urtasun RC, Wasserman TH, Hancock S, Harris JW, Halsey J, Hirst VK.
    Int J Radiat Oncol Biol Phys; 1984 Sep 01; 10(9):1749-53. PubMed ID: 6237086
    [Abstract] [Full Text] [Related]

  • 6. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
    Saunders ME, Dische S, Anderson P, Flockhart IR.
    Br J Cancer Suppl; 1978 Jun 01; 3():268-70. PubMed ID: 209808
    [Abstract] [Full Text] [Related]

  • 7. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S, Saunders MI, Flockhart IR.
    Br J Cancer Suppl; 1978 Jun 01; 3():318-21. PubMed ID: 209811
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of hypoxic cell radiosensitizers: a review.
    Workman P.
    Cancer Clin Trials; 1980 Jun 01; 3(3):237-51. PubMed ID: 7438321
    [Abstract] [Full Text] [Related]

  • 9. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
    Kogelnik HD, Meyer JH, Jentzsch K, Szepesi T, Kärcher KH, Maida E, Mamoli B, Wessely P, Zaunbauer F.
    Br J Cancer Suppl; 1978 Jun 01; 3():281-5. PubMed ID: 209810
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and toxicology of continuously infused nitroimidazoles.
    Eifel PJ, Brown JM.
    Int J Radiat Oncol Biol Phys; 1984 Aug 01; 10(8):1311-4. PubMed ID: 6236186
    [Abstract] [Full Text] [Related]

  • 11. [Radiosensitizer: hypoxic cell radiosensitizer].
    Mori T.
    Gan To Kagaku Ryoho; 1989 Apr 01; 16(4 Pt 2-2):1399-404. PubMed ID: 2525001
    [Abstract] [Full Text] [Related]

  • 12. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
    Newman HF, Bleehen NM, Workman P.
    Int J Radiat Oncol Biol Phys; 1986 Jul 01; 12(7):1113-6. PubMed ID: 2943709
    [Abstract] [Full Text] [Related]

  • 13. [Radiosensitization by hypoxic cell radiosensitizer--present status of radiosensitizer].
    Murayama C, Mori T.
    Gan No Rinsho; 1990 Oct 01; 36(13):2249-54. PubMed ID: 2147449
    [Abstract] [Full Text] [Related]

  • 14. Bone marrow toxicity of total-body irradiation combined with radiosensitizers.
    Shields AF, Applebaum FR, Graham T, Deeg HJ, Allalunis-Turner J, Chapman JD, Storb R.
    Radiat Res; 1989 Nov 01; 120(2):364-9. PubMed ID: 2533359
    [Abstract] [Full Text] [Related]

  • 15. [Present status of radiation sensitizers--hypoxic cell radiosensitizer].
    Murayama C, Mori T.
    Gan To Kagaku Ryoho; 1989 Jun 01; 16(6):2135-41. PubMed ID: 2660744
    [Abstract] [Full Text] [Related]

  • 16. Peripheral neuropathy related to misonidazole: incidence and pathology.
    Urtasun RC, Chapman JD, Feldstein ML, Band RP, Rabin HR, Wilson AF, Marynowski B, Starreveld E, Shnitka T.
    Br J Cancer Suppl; 1978 Jun 01; 3():271-5. PubMed ID: 209809
    [Abstract] [Full Text] [Related]

  • 17. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
    White RA, Workman P, Brown JM.
    Radiat Res; 1980 Dec 01; 84(3):542-61. PubMed ID: 6450431
    [No Abstract] [Full Text] [Related]

  • 18. Clinical trials of misonidazole in the United States.
    Wasserman TH, Stetz J, Phillips TL.
    Cancer Clin Trials; 1981 Dec 01; 4(1):7-16. PubMed ID: 7214664
    [Abstract] [Full Text] [Related]

  • 19. Clinical trials of radiosensitizers: what should we expect?
    Brown JM.
    Int J Radiat Oncol Biol Phys; 1984 Mar 01; 10(3):425-9. PubMed ID: 6231272
    [Abstract] [Full Text] [Related]

  • 20. Radiosensitization, pharmacokinetics, and toxicity of a 2-nitroimidazole nucleoside (RA-263).
    Agrawal KC, Rupp WD, Rockwell S.
    Radiat Res; 1986 Feb 01; 105(2):227-39. PubMed ID: 3754053
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.